PATH strives for vaccine equity in response to COVID-19
When COVID-19 emerged, we mobilized quickly and deployed our decades of experience advancing equitable access to vaccines and immunization to support the global COVID-19 response.
Through the PATH Center for Vaccine Innovation and Access (CVIA), our COVID-19 work spans the full vaccine development to delivery spectrum, including supporting country vaccine readiness; COVAX and other efforts to ensure equitable access to vaccine; vaccine development and manufacturing scale-up; vaccine clinical evaluation; immunization system resiliency; and other efforts.
-
November 11, 2022Pneumonia can occur across life’s stages—prevention should too
-
August 3, 2022Latest childhood immunization data must spur renewed action
-
August 2, 2022Pakistan's TikTok campaign for COVID-19 information
-
December 21, 2023Vaccinating 65,000 people in two days
-
August 16, 2024Can COVID-19 inspire progress in maternal immunization?
-
March 10, 2022Endemic is not the end—it never has been
Other reading
-
Understanding the journey to herd immunity
-
Striking a balance: Resuming routine immunization in India
-
When a COVID-19 vaccine is ready, will the world be?
-
3 ways immunization data tools are flexing to fight COVID-19 in Africa
-
Avoiding the “double whammy”: PATH advances immunization in the time of COVID
-
Why the COVID-19 epidemic is not a surprise